MARKET

EIGR

EIGR

Eiger
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.30
-0.10
-1.19%
After Hours: 8.30 0 0.00% 16:00 04/16 EDT
OPEN
8.47
PREV CLOSE
8.40
HIGH
8.47
LOW
8.10
VOLUME
135.80K
TURNOVER
--
52 WEEK HIGH
13.99
52 WEEK LOW
6.76
MARKET CAP
281.38M
P/E (TTM)
-3.5720
1D
5D
1M
3M
1Y
5Y
Wednesday 4/14 Insider Buying Report: RAPT, EIGR
Apr 14, 2021 (MarketNewsVideo.com via COMTEX) -- As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to...
MarketNewsVideo.com · 3d ago
8-K: Eiger BioPharmaceuticals, Inc.
(EDGAR Online via COMTEX) -- CA false 0001305253 0001305253 2021-04-05 2021-04-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/09 21:48
Global Congenital Hyperinsulinism Market 2020 Technological Strategies, Business Advancements and Top-Vendor Landscape to 2025
Mar 29, 2021 (CDN Newswire via Comtex) -- MarketsandResearch.biz has published a report titled Global Congenital Hyperinsulinism Market Growth (Status and...
CDN Newswire · 03/29 19:55
Are Insiders Buying Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Stock?
Simply Wall St. · 03/24 08:55
Eiger Biopharmaceuticals (EIGR) Received its Third Buy in a Row
After Ladenburg Thalmann & Co. and Wedbush gave Eiger Biopharmaceuticals (NASDAQ: EIGR) a Buy rating last month, the company received another Buy,
SmarterAnalyst · 03/11 12:41
Eiger Biopharmaceuticals (EIGR) Receives a Buy from Wedbush
Wedbush analyst Liana Moussatos reiterated a Buy rating on Eiger Biopharmaceuticals (EIGR) today and set a price target of $23.00. The company's shares
SmarterAnalyst · 03/10 16:45
Eiger Biopharmaceuticals (EIGR) Receives a Buy from Ladenburg Thalmann & Co.
SmarterAnalyst · 03/10 11:45
Eiger BioPharmaceuticals (EIGR) Reports Q4 Loss, Lags Revenue Estimates
Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -275.76% and -100.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 03/09 23:25
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EIGR. Analyze the recent business situations of Eiger through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EIGR stock price target is 31.67 with a high estimate of 49.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 123
Institutional Holdings: 26.43M
% Owned: 77.95%
Shares Outstanding: 33.90M
TypeInstitutionsShares
Increased
42
3.78M
New
13
787.97K
Decreased
19
662.85K
Sold Out
24
2.64M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Independent Director
Thomas Dietz
President/Chief Executive Officer/Director
David Cory
Chief Financial Officer
Sriram Ryali
Executive Vice President
Eldon Mayer
Other
James Shaffer
Director
David Apelian
Independent Director
Jeffrey Glenn
Independent Director
Evan Loh
Independent Director
Christine Murray
Independent Director
Amit Sachdev
Director
Patrick Y. Yang
No Data
About EIGR
Eiger BioPharmaceuticals Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing drugs for serious diseases. Its product candidate pipeline includes programs, including Lonafarnib (LNF), Peginterferon Lambda (lambda), LNF in Progeria and Progeroid Laminopathies (PL), Avexitide. LNF is an orally bioavailable, farnesylation inhibitor in Phase-III clinical trials for Hepatitis Delta Virus (HDV) infection. Lambda is a late-stage, type III interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. It is also developing lonafarnib for treatment of Progeria and Progeroid Laminopathies. Avexitide is a peptide that it is being developed as a treatment for Post-Bariatric Hypoglycemia (PBH). Avexitide is also being developed for Congenital Hyperinsulinism (CHI).

Webull offers kinds of Eiger Biopharmaceuticals Inc stock information, including NASDAQ:EIGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EIGR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EIGR stock methods without spending real money on the virtual paper trading platform.